67,069 Shares in Mereo BioPharma Group plc (NASDAQ:MREO) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in Mereo BioPharma Group plc (NASDAQ:MREO) during the third quarter, HoldingsChannel reports. The fund acquired 67,069 shares of the company’s stock, valued at approximately $276,000.

Several other large investors also recently made changes to their positions in the business. Deerfield Management Company L.P. Series C bought a new position in shares of Mereo BioPharma Group in the second quarter valued at about $24,158,000. Janus Henderson Group PLC acquired a new stake in Mereo BioPharma Group in the 1st quarter valued at about $16,949,000. Frazier Life Sciences Management L.P. bought a new position in shares of Mereo BioPharma Group in the second quarter worth about $15,845,000. Rubric Capital Management LP raised its stake in shares of Mereo BioPharma Group by 12.9% in the second quarter. Rubric Capital Management LP now owns 15,307,347 shares of the company’s stock worth $55,106,000 after acquiring an additional 1,754,350 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new position in shares of Mereo BioPharma Group during the second quarter worth approximately $4,512,000. Institutional investors own 62.83% of the company’s stock.

Mereo BioPharma Group Trading Up 1.1 %

Shares of Mereo BioPharma Group stock opened at $3.72 on Friday. Mereo BioPharma Group plc has a 52 week low of $3.17 and a 52 week high of $5.02. The firm has a fifty day moving average of $4.15 and a two-hundred day moving average of $3.96.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Tuesday, November 12th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $7.50.

Insider Activity at Mereo BioPharma Group

In other Mereo BioPharma Group news, CFO Christine Ann Fox sold 9,128 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $4.47, for a total value of $40,802.16. Following the completion of the sale, the chief financial officer now directly owns 108,443 shares in the company, valued at $484,740.21. This represents a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Denise Scots-Knight sold 28,611 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $4.47, for a total value of $127,891.17. Following the completion of the transaction, the chief executive officer now owns 868,967 shares of the company’s stock, valued at $3,884,282.49. This represents a 3.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,931 shares of company stock worth $236,602. 4.13% of the stock is owned by insiders.

Mereo BioPharma Group Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.